$16.34
+1.39 (+9.30%)
Open$15.40
Previous Close$14.95
Day High$16.35
Day Low$15.11
52W High$44.54
52W Low$30.30
Volume—
Avg Volume644.8K
Market Cap208.96M
P/E Ratio41.14
EPS$0.81
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+149.3% upside
Current
$16.34
$16.34
Target
$40.74
$40.74
$28.14
$40.74 avg
$50.62
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 84.57M | 86.26M | 76.53M |
| Net Income | -20,699,385 | -25,319,011 | -23,908,785 |
| Profit Margin | -24.5% | -29.4% | -31.2% |
| EBITDA | -24,990,141 | -25,196,528 | -24,930,968 |
| Free Cash Flow | -20,292,095 | -20,848,476 | -17,728,438 |
| Rev Growth | +3.2% | +20.0% | +0.5% |
| Debt/Equity | 0.58 | 0.68 | 0.63 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |